Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

26/03/2014 New companies in the UAB Research Park 18/03/2014 The public-private partnership ESTEVE-UAB is bearing fruit 11/03/2014 Barcelona ranked fourth place among the most attractive European cities for investors 24/02/2014 Zero2infinity offers sightseeing flights in the stratosphere 18/02/2014 Students from Harvard visited the Barcelona Synchrotron Park and ALBA 11/02/2014 Applications of the Alba synchrotron in the materials and chemistry industries
42 43 44 45 46 47 48 49